Phase II Trial of Axicabagene Ciloleucel and Glofitamab As Second-Line Therapy for Patients with Relapsed or Refractory Large B-Cell Lymphoma

Kunhwa Kim(The University of Texas MD Anderson Cancer Center), Jason R. Westin(The University of Texas MD Anderson Cancer Center), Luis Fayad(The University of Texas MD Anderson Cancer Center), Sairah Ahmed(The University of Texas MD Anderson Cancer Center), Paolo Strati(The University of Texas MD Anderson Cancer Center), Dai Chihara(The University of Texas MD Anderson Cancer Center), Michael R. Green(Harvard University), Sattva S. Neelapu(The University of Texas MD Anderson Cancer Center), Frederick Hagemeister(The University of Texas MD Anderson Cancer Center), Fateeha Furqan, Chijioke Nze(The University of Texas MD Anderson Cancer Center), Christopher R. Flowers(The University of Texas MD Anderson Cancer Center), Preetesh Jain(The University of Texas MD Anderson Cancer Center), Amrita Chauhan(Unknown), Michael Wang(St. Joseph Health System), Swaminathan P. Iyer(The University of Texas MD Anderson Cancer Center)
Blood
November 5, 2024
10.1182/blood-2024-205196
Cited by 4

Related Papers

Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma
|Blood|2010|1.3k
2016 US lymphoid malignancy statistics by World Health Organization subtypes
|CA A Cancer Journal for Clinicians|2016|1.1k
Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials
|JAMA Oncology|2019|829
Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium
|Journal of Clinical Oncology|2020|782
Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas
|Nature Medicine|2020|593